KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Eli Lilly (LLY) Net Margin (2016 - 2025)

Historic Net Margin for Eli Lilly (LLY) over the last 16 years, with Q4 2025 value amounting to 34.41%.

  • Eli Lilly's Net Margin rose 18200.0% to 34.41% in Q4 2025 from the same period last year, while for Dec 2025 it was 31.67%, marking a year-over-year increase of 81600.0%. This contributed to the annual value of 31.67% for FY2025, which is 81600.0% up from last year.
  • As of Q4 2025, Eli Lilly's Net Margin stood at 34.41%, which was up 18200.0% from 31.72% recorded in Q3 2025.
  • Eli Lilly's Net Margin's 5-year high stood at 36.38% during Q2 2025, with a 5-year trough of 0.6% in Q3 2023.
  • Over the past 5 years, Eli Lilly's median Net Margin value was 21.63% (recorded in 2021), while the average stood at 22.27%.
  • Its Net Margin has fluctuated over the past 5 years, first tumbled by -215200bps in 2023, then surged by 232300bps in 2025.
  • Over the past 5 years, Eli Lilly's Net Margin (Quarter) stood at 21.58% in 2021, then increased by 23bps to 26.54% in 2022, then decreased by -12bps to 23.41% in 2023, then surged by 39bps to 32.59% in 2024, then grew by 6bps to 34.41% in 2025.
  • Its Net Margin was 34.41% in Q4 2025, compared to 31.72% in Q3 2025 and 36.38% in Q2 2025.